CAS: 1899921-05-1

Almonertinib

HS-10296 is a novel pharmaceutical compound that functions as a specific inhibitor of EGFR (epidermal growth factor receptor), which is a key therapeutic target in certain cancer pathways. This compound is derived from a synthetic source, meticulously designed to target and interrupt the signaling pathways involved in tumor proliferation and survival. The mode of action of HS-10296 involves the competitive inhibition of the ATP-binding domain of EGFR tyrosine kinase, thereby preventing phosphorylation and subsequent activation of downstream signaling proteins involved in cell division and survival. Primarily, HS-10296 is utilized in the treatment of non-small cell lung cancer (NSCLC) cases that exhibit EGFR mutations. Its application is particularly valuable in instances where resistance to first-generation EGFR inhibitors has developed, making HS-10296 an important addition to targeted cancer therapies. This compound is administered with the objective of controlling and reducing tumor growth, ultimately prolonging patient survival and enhancing quality of life through more efficacious management of advanced-stage malignancies. Its development and application underscore the progress in personalized medicine, aligning treatment plans with specific genetic profiles of patients.

Almonertinib (HS-10296) is an inhibitor of EGFR activation mutation and tolerant mutation of EGFR T790M, which has only limited activity against wild-type EGFR.